Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Immunotherapy
•
Renal Cell Carcinoma
•
NCI-CCC Tumor Board Question
•
Duke
•
NCI-CCC GU Tumor Board Question
In a patient with metastatic RCC who discontinued nivolumab after a prolonged response to ipilimumab/nivolumab, would you consider re-starting nivolumab at disease progression?
Related Questions
What is your approach to systemic treatment of de novo metastatic hormone-sensitive prostate ductal adenocarcinoma with lung only metastases?
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
What is your treatment approach in localized RCC with VHL mutation after progression on belzutifan?
How would you approach the use of bevacizumab in metastatic FH-deficient RCC/HLRCC that is c/b extensive IVC tumor thrombus and DVT/PE?
What is your preferred approach to low volume unresectable/metastatic favorable risk RCC?
Would you use adjuvant pembrolizumab for bilateral ccRCC with R1 resection?
How would you treat a patient with metastatic RCC with high grade neuroendocrine and sarcomatoid features after progression on IO + TKI?
How would you approach adjuvant systemic therapy for an isolated, oligometastatic CNS recurrence of RCC that was treated with SBRT?
When, if ever, would you re-challenge with immunotherapy for patients with metastatic RCC?
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?